RE-BVS – Piemonte Repository

Sfoglia per AUTORE
KARLIN L
Collezione AOU Città della Salute di Torino

Items : 5

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X.

2025
AOU Città della Salute di Torino

Mina R; Mylin AK; Yokoyama H; Magen H; Alsdorf W; Minnema MC; Shune L; Isufi I; Harrison SJ; Shah UA; Schecter JM; Vogel M; Lendvai N; Gries KS; Katz EG; Slaughter A; Lonardi C; Gilbert J; Li Q; Deraedt W; Filho OC; Patel N; Florendo E; Karlin L; Weisel K;

30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis. in HemaSphere / Hemasphere. 2024 Nov 5;8(11):e70041. doi: 10.1002/hem3.70041. eCollection 2024 Nov.

2024
AOU Città della Salute di Torino

Ocio EM; Perrot A; Moreau P; Mateos MV; Bringhen S; Martínez-López J; Karlin L; Wang SY; Oprea C; Li Y; Kodas E; San-Miguel J;

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation. in Leukemia / Leukemia. 2023 Jul;37(7):1521-1529. doi: 10.1038/s41375-023-01936-7. Epub 2023 Jun 14.

2023
AOU Città della Salute di Torino

Ocio EM; Perrot A; Bories P; San-Miguel JF; Blau IW; Karlin L; Martinez-Lopez J; Wang SY; Bringhen S; Marcatti M; Mateos MV; Rodriguez-Otero P; Oliva S; Nogai A; Le Roux N; Dong L; Macé S; Gassiot M; Fitzmaurice T; Oprea C; Moreau P;

Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. in Leukemia research / Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29.

2021
AOU Città della Salute di Torino

Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG;

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. in The Lancet. Haematology / Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.

2016
AOU Città della Salute di Torino

Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C;